Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Tepotinib (MSC2156119J) in Patients with solid cancers harboring c-MET amplification or exon 14 mutation Who Progressed after Standard treatment for Metastatic disease

Next Previous
Trial Profile

A Phase II Study of Tepotinib (MSC2156119J) in Patients with solid cancers harboring c-MET amplification or exon 14 mutation Who Progressed after Standard treatment for Metastatic disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tepotinib (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms KM-08

Most Recent Events

  • 04 Jun 2024 Results assessing plasma ctDNA as a potential biomarker in MET-dysregulated advanced cancer patients with tepotinib treatment, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 24 Oct 2023 Results (n=35) assessing the efficacy and safety of tepotinib in patients with various solid cancers harboring MET exon 14 skipping mutation (METex14) or MET gene amplification, presented at the 48th European Society for Medical Oncology Congress.
  • 05 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top